Myasthenia Gravis News and Research

RSS
Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal (voluntary) muscles of the body. The hallmark of myasthenia gravis is muscle weakness that increases during periods of activity and improves after periods of rest. Muscles that control eye and eyelid movements, facial expression, chewing, talking, and swallowing are often, but not always, involved. The muscles that control breathing and neck and limb movements may also be affected. Myasthenia gravis is caused by a defect in the transmission of nerve impulses to muscles. Normally when impulses travel down the nerve, the nerve endings release a neurotransmitter substance called acetylcholine. In myasthenia gravis, antibodies produced by the body's own immune system block, alter, or destroy the receptors for acetylcholine. The first noticeable symptoms of myasthenia gravis may be weakness of the eye muscles, difficulty in swallowing, or slurred speech. Symptoms vary in type and severity. Myasthenia gravis is not directly inherited nor is it contagious.
More data, more answers? A 1.9 million-person health study shows why scale has limits

More data, more answers? A 1.9 million-person health study shows why scale has limits

UC San Diego study reveals genetic causes of rare neuromuscular disorders

UC San Diego study reveals genetic causes of rare neuromuscular disorders

CAR-T cell therapy shows promise for treating rheumatoid arthritis

CAR-T cell therapy shows promise for treating rheumatoid arthritis

Pregnancy not linked to increased myasthenia gravis flare-up risk

Pregnancy not linked to increased myasthenia gravis flare-up risk

Early myocarditis onset after immunotherapy linked to higher fatality risk

Early myocarditis onset after immunotherapy linked to higher fatality risk

Understanding the trends of various neurological disorders in the Chinese population

Understanding the trends of various neurological disorders in the Chinese population

Rozanolixizumab prevents congenital heart block in high-risk pregnancy

Rozanolixizumab prevents congenital heart block in high-risk pregnancy

Early immunotherapy shows promise for treating anti-IgLON5 disease

Early immunotherapy shows promise for treating anti-IgLON5 disease

CAR T-cell therapy successfully treats rare autoimmune disease of the peripheral nervous system

CAR T-cell therapy successfully treats rare autoimmune disease of the peripheral nervous system

First patient treated in international clinical trial for rare muscle-weakness disease

First patient treated in international clinical trial for rare muscle-weakness disease

New insights into how myasthenia gravis antibodies disrupt muscle function

New insights into how myasthenia gravis antibodies disrupt muscle function

New review maps the impact of reproductive hormones on neurological health

New review maps the impact of reproductive hormones on neurological health

Emory researchers discover enzyme to combat IgG-mediated disorders

Emory researchers discover enzyme to combat IgG-mediated disorders

Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis

Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis

Microbial biomarkers identified in lupus and IBD offer pathways for targeted therapies

Microbial biomarkers identified in lupus and IBD offer pathways for targeted therapies

Rare but real: The neurological risks associated with vaccines

Rare but real: The neurological risks associated with vaccines

Investigational drug shows promise in treating rare blood disease in fetuses

Investigational drug shows promise in treating rare blood disease in fetuses

Powerful visualization technologies offer new insight into understanding muscle contraction in humans

Powerful visualization technologies offer new insight into understanding muscle contraction in humans

Innovative CAR T cell therapy shows promise for relapsed CIDP patients

Innovative CAR T cell therapy shows promise for relapsed CIDP patients

World-first discovery offers potential cure for lupus

World-first discovery offers potential cure for lupus

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.